While carriers of CMP-associated variants with a history of HF had a numerically higher risk compared with noncarriers, this did not reach statistical significance (HR 2.98, 95% CI 0.88–10.20; P = 0.08).
← all excerpts
Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.
1
0.0800
0.0800